The new report titled ‘Global Oncolytic Virus Therapies Market’, published by emergen research, is methodically curated by our team of analysts, keeping readers’ understanding in mind, and includes a wide-ranging database of industry distribution. The report takes a closer look at the historical and current market scenarios to accurately predict the global Oncolytic Virus Therapies market outlook over the forecast duration (2019-2027).
Moreover, the report offers the latest coverage of the massive impact of the COVID-19 pandemic on the worldwide Oncolytic Virus Therapies industry. The globally-disrupting incidence has impacted nearly every aspect of this business domain. However, the latest study expounds on the present market scenario and forecasts the pandemic’s aftermath, with respect to this industry. Furthermore, the major aspects of the market have been discussed in the report, with expert opinions on the current status of the market.
Get a Free sample of the report : https://www.emergenresearch.com/request-sample/704
Governments in developing countries are taking initiatives to create awareness regarding different causes of cancer. Advancement in technology facilitates development of cost-effective therapies and pipeline projects, which is driving the growth of oncolytic virus therapies market. Various awareness campaigns are being conducted to encourage people to opt for early diagnosis which will increase the patient pool of oncolytic virus therapy. However, there are some common side-effects of the therapy, which include chills, nausea, fatigue, fever, flu-like symptoms, and injection site pain. This hinders oncolytic virus therapies market revenue growth.
The report offers a comprehensive overview of the competitive landscape and covers company profiles, production and manufacturing capacity, product portfolio, expansion strategies, and business initiatives such as mergers and acquisitions, joint ventures, collaborations, partnerships, and product launches and brand promotions among others.
Some Key Highlights in the Report
In January 2021, Enara Bio and Boehringer Ingelheim announced a strategic collaboration and licensing agreement for RD of novel targeted cancer immunotherapy. The new collaboration combines Boehringer’s approach to treat cancer through pairing science with innovative platforms such as oncolytic virus and cancer vaccines, with Enara’s expertise in cancer antigen identification.
Breast cancer is among the second most diagnosed cancer across the globe and current treatments are insufficient to cure metastatic breast cancer often associated with severe side effects which destroys patient’s quality of life. Oncolytic virus therapies has emerged as a relevant tool to target different kinds of cancer such as breast cancer. For instance, Pelareorep is an unmodified and intravenously delivered oncolytic virus which primes an immune response among patients with breast cancer.
Rise in number of research institutes for development of effective therapies and drugs to treat and study cancer, particularly in developing countries, is driving the growth of cancer research institute segment. Increased investment by private and government sectors into these institutions is driving segment growth.
North America accounted for the largest revenue share in 2020. The U.S. is the primary contributor and is expected to witness high growth due to the large amount of funding by the private firms and government for clinical trials. Other factors driving the oncolytic virus therapies market are an increase in research and development initiatives to develop therapeutic options for chronic diseases, easy approval for clinical trials, and availability of highly sophisticated research infrastructure.
Key players in the market include Oncolytics Biotech, Inc., Amgen Inc., Sorrento Therapeutics, Inc., Transgene SA, Daiichi Sankyo Company, Limited, Shanghai Sunway Biotech Co., Ltd., Takara Bio Inc., PsiOxus Therapeutics, SillaJen, Inc., and ViroCure.
Request customization of the report: https://www.emergenresearch.com/request-for-customization/704
Regional Overview:
The global Oncolytic Virus Therapies market has been categorized on the basis of key geographical regions into North America, Asia Pacific, Europe, Latin America, and Middle East Africa. It evaluates the presence of the global Oncolytic Virus Therapies market in the major regions with regards to market share, market size, revenue contribution, sales network and distribution channel, and other key elements.
Emergen Research has segmented the global oncolytic virus therapies market on the basis of virus type, application, end-use, and region:
Virus Type Outlook (Revenue, USD Million; 2018–2028)
- Genetically Engineered Oncolytic Viruses
- Herpes Simplex Virus
- Adenovirus
- Vaccinia Virus
- Oncolytic Wild-Type Viruses
- Reovirus
- Newcastle Disease Virus
- Vesicular Stomatitis Virus
Application Outlook (Revenue, USD Million; 2018–2028)
- Solid Tumors
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Glioblastoma
- Melanoma
- Hematological Malignancies
- Lymphoma
- Leukemia
- Myeloma
End-use Outlook (Revenue, USD Million; 2018–2028)
- Hospitals
- Specialty Clinics
- Cancer Research Institute
Unfolding the prime factors prompting global Oncolytic Virus Therapies market growth:
The study offers an in-depth analysis of the product outlook, which depicts the latest production growth trends and profit valuation. It further fragments the global Oncolytic Virus Therapies market into a broad product spectrum.
The study covers essential data related to these products’ application landscape, the demand for and market share held by each application type, and their growth rate analysis over the estimated period.
Read More: https://www.emergenresearch.com/industry-report/oncolytic-virus-therapies-market
Related Reports:
flow imaging microscopy market
digital payment market
rna transcriptomics market
blood-brain barrier market
project portfolio management market
near infrared spectroscopy market
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs
"
